|By Business Wire||
|August 12, 2014 06:09 AM EDT||
Artilysin®, a new and innovative technological approach in the fight against pathogenic and multi-resistant bacteria, developed by the research & development company Lysando, has arrived in the pharmaceutical industry. Boehringer Ingelheim Vetmedica has secured the licensing rights for the technology platform Artilysin®. The company is hopeful to receive significant momentum and solutions from this new substance class for the problem of multi-resistant bacteria, which also is an increasing threat to the animal world.
Artilysin®s are proteins that, through a physical mechanism, selectively eliminate pathogenic, multi-resistant and persisting bacteria. By way of license, Boehringer Ingelheim Vetmedica is taking advantage of the possibilities presented by this technology. The scope of applications for Artilysin®s spans from human and animal medicine to the food industry and the area of hygiene. They work quickly and with their “friend or foe” identification very specifically and are completely biodegradable. Additionally, no resistances occurred during the expansive studies. Multi-resistant bacteria pose a significant threat to health due to the increasing ineffectiveness of antibiotics. The EU Commission estimates the annual number of deaths caused by multi-resistant bacteria at 25,000. Massive economic effects are linked to this fact.
The Boehringer Ingelheim Group is among the 20 leading pharmaceutical companies worldwide. Their focus areas include research & development, production and marketing of new medicines with significant therapeutic benefits for human and animal health. In 2013, Boehringer Ingelheim reported revenues of appr. 14.1 bn Euros.
Lysando itself is not a manufacturer of pharmaceutical products nor will it become one in the future; it only provides its new technology platform through licensing. „The acquisition of licensing rights for the Artilysin® technology by Boehringer Ingelheim Vetmedica is a decisive step in the acceptance of this new class of substances“, explains Markus Matuschka v. Greiffenclau, CEO of Lysando AG.
Lysando AG is a technology leader in the area of antimicrobial proteins. Since its foundation in 2009, the privately financed research company has done research on artificial designer proteins with a team of scientists in the town of Regensburg. Artilysin®s represent a revolutionary breakthrough in the battle against multi-resistant bacteria. With this new technology platform, drugs and substances against pathogenic gram-negative and gram-positive bacteria can be specifically developed, both for antibiotic-resistant and persisting bacteria. With Artilysin®s, Lysando has created an effective alternative to antibiotics.
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Jul. 31, 2015 12:47 PM EDT
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Jul. 31, 2015 11:45 AM EDT Reads: 123
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Jul. 31, 2015 11:45 AM EDT Reads: 117
Jul. 31, 2015 10:50 AM EDT
Jul. 31, 2015 10:00 AM EDT Reads: 140
Jul. 31, 2015 08:45 AM EDT Reads: 301
Jul. 31, 2015 08:00 AM EDT Reads: 158
Jul. 30, 2015 07:30 PM EDT Reads: 1,399
Jul. 30, 2015 06:30 PM EDT Reads: 889
Jul. 30, 2015 06:00 PM EDT Reads: 1,803
Jul. 30, 2015 05:00 PM EDT Reads: 1,090
Jul. 30, 2015 04:00 PM EDT Reads: 2,205
Jul. 30, 2015 03:45 PM EDT Reads: 452
Jul. 30, 2015 03:00 PM EDT Reads: 488
Jul. 30, 2015 03:00 PM EDT Reads: 1,741